drugset / Trial / NCT05969743
Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease
NaSingle-groupOpen-labelPrevention
Summary
Explore the tolerability and efficacy of letermovir in the prevention of CMV reactivation in patients with acute and chronic graft-versus-host disease (GVHD) beyond day 100.
Timeline
- Start
- 2023-10-01
- Primary completion
- 2025-04-30
- Completion
- 2025-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Letermovir | Small molecule | 240 mg | — |
| Subject | Letermovir | Small molecule | 480 mg | — |